Skip to main content
MADRIGAL PHARMACEUTICALS, INC. logo

MADRIGAL PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · MDGL ISIN · US5588681057 LEI · 549300CHIMT2EUSNJB60 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2018-05-08 Earnings Release
Country US United States of America
Listing US MDGL

About MADRIGAL PHARMACEUTICALS, INC.

https://www.madrigalpharma.com/

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive liver disease with high unmet medical need. The company's research led to the first U.S. Food and Drug Administration (FDA)-approved treatment for MASH. Madrigal's therapeutic goal is to halt or reverse liver scarring (fibrosis) and resolve the disease before patients experience severe complications, including cirrhosis, liver failure, and the need for transplantation.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 8, 2018, reporting the company's financial results for the first fiscal quarter ended March 31, 2018. It specifically states that the company issued a press release announcing these financial results, and the press release is furnished as an exhibit. The document itself is short (3685 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis. According to the 'MENU VS MEAL' rule, such a document is classified as an Earnings Release (ER) because it is the initial announcement of quarterly financial results with key highlights only, not a full interim or annual report.
2018-05-08 English
10-Q
Interim / Quarterly Report Q1 2018
2018-05-08 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Madrigal Pharmaceuticals, Inc. It registers additional shares under the company's Amended 2015 Stock Plan. The text includes details about the securities to be registered, calculation of registration fees, incorporation by reference of prior filings, and signatures of company officers. Form S-8 is specifically used for registering securities to be offered under employee benefit plans, stock options, or similar plans. This type of filing is related to share issuance and capital changes rather than financial results, management changes, or other report types. Therefore, the document fits the category of Share Issue/Capital Change announcements.
2018-04-27 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or definitive additional materials related to a shareholder meeting. It includes information about the meeting date, voting instructions, election of directors, ratification of auditors, and advisory vote on executive compensation. The presence of proxy materials and voting instructions indicates this is a Proxy Solicitation & Information Statement. The document is about soliciting shareholder votes and providing information for the meeting, not the actual meeting minutes or voting results. Therefore, the correct classification is PSI (Proxy Solicitation & Information Statement). The document length (5720 characters) supports it being a full proxy statement rather than a brief announcement or notice.
2018-04-27 English
DEF 14A
Proxy Solicitation & Information Statement
2018-04-27 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 13, 2018, by Madrigal Pharmaceuticals, Inc. It announces the issuance of a press release regarding the company's financial results for the fourth quarter and fiscal year ended December 31, 2017. The text explicitly states that the press release is furnished as an exhibit and incorporated by reference, and that the information is not deemed filed for purposes of Section 18 of the Exchange Act. The document itself does not contain detailed financial statements or substantive financial data but rather serves as a current report announcing the results and providing the press release. Given the length of the document (3699 characters) and its nature as a current report announcing financial results, this fits the definition of an Earnings Release (ER) rather than a full Annual Report (10-K) or Interim Report (IR).
2018-03-13 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.